

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS PO Box 1430 Alexandra, Virginia 22313-1450 www.wopto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/663,450	09/15/2003	Merja E. Penttila	GC590-2-C1	2737
7590 03/20/2008 Genencor International, Inc. 925 Page Mill Road			EXAMINER	
			GUZO, DAVID	
Pola Alto, CA	94034-1013		ART UNIT	PAPER NUMBER
			1636	
			MAIL DATE	DELIVERY MODE
			03/20/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Application No. Applicant(s) 10/663 450 PENTTILA ET AL. Office Action Summary Examiner Art Unit David Guzo 1636 -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS. WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status 1) Responsive to communication(s) filed on 22 January 2008. 2a) This action is FINAL. 2b) This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4) Claim(s) 2.3.5-13.26-34.83-85.87 and 89-98 is/are pending in the application. 4a) Of the above claim(s) 83-85 and 87 is/are withdrawn from consideration. 5) Claim(s) _____ is/are allowed. 6) Claim(s) 2.3.5-13.26-34.90.93.94 and 98 is/are rejected. 7) Claim(s) 89,91,92 and 95-97 is/are objected to. 8) Claim(s) are subject to restriction and/or election requirement. Application Papers 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are; a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abevance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. Attachment(s) 1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413) Paper No(s)/Mail Date. Notice of Draftsparson's Catent Drawing Review (CTO-948)

Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _______

5) Notice of Informal Patent Application

6) Other:

Application/Control Number: 10/663,450

Art Unit: 1636

Detailed Action

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 1/22/08 has been entered.

35 USC 112,1st Paragraph Rejections

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 2, 3, 5-13, 26-34, 90, 93-94 and 98 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Applicants' arguments with regard to the previous grounds of rejection under 35 USC 112, 1st Paragraph (NEW MATTER) are persuasive and said grounds of rejection are withdrawn. However, the following claimed subject matter is not supported by the application, as filed. Applicants recite, in Claim 2, a method of increasing the secretion of a heterologous protein in a fungal cell, comprising inducing an unfolded protein

Application/Control Number: 10/663,450

Art Unit: 1636

response (UPR) by increasing the presence of a HAC1 UPR- modulating protein in said fungal cell, comprising transforming the fungal cell with a nucleic acid encoding a yeast or filamentous fungal HAC1 UPR-modulating protein comprising a DNA binding domain having at least 90% sequence identity to a DNA binding domain of amino acid residues 45 -109 of SEQ ID No:19, and increasing secretion of the heterologous protein relative to secretion of the heterologous protein in a parental cell, wherein said fungal cell is a yeast or filamentous fungal cell. The application, as filed does not provide support for transforming the fungal cell with a nucleic acid encoding a yeast or filamentous fungal HAC1 UPR-modulating protein comprising a DNA binding domain having at least 90% sequence identity to a DNA binding domain of amino acid residues 45 -109 of SEQ ID No:19. This is a NEW MATTER rejection.

Claims 89, 91-92 and 95-97 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

No Claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David Guzo, Ph.D., whose telephone number is (571) 272-0767. The examiner can normally be reached on Monday-Thursday from 8:00 AM to 5:30 PM. The examiner can also be reached on alternate Fridays.

Art Unit: 1636

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph Woitach, Ph.D., can be reached on (571) 272-0739. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

March 13, 2008

/David Guzo/ Primary Examiner Art Unit 1636